Company: GANX
Filing Date: 2025-04-10
Form Type: 8-K
Source: 0001104659-25-033797
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-10
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01. Regulation FD Disclosure.

On April 10, 2025, Gain Therapeutics, Inc.
(the “ Company”) issued a press release announcing the presentation of additional preclinical data and design of the Company’s
Phase 1b clinical study of GT-02287, the Company’s lead allosteric small molecule in development for the treatment of Parkinson’s
disease with or without a GBA1 mutation. A copy of the press release is furnished as Exhibit 99.1.

The Company updated its investor presentation.
A copy of the investor presentation is furnished as Exhibit 99.2.

The information in this Current Report on Form 8-K
under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission,
and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “ Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by a specific reference in such filing.

Item 8.01. Other Events.